While pharmaceutical revenues are traditionally derived from a few products that are heavily marketed, decreasing R&D productivity together with pricing and reimbursement hurdles are driving change in the industry. The emergence of novel and advanced therapies is also creating new opportunities. Economic expansion and increasing affluence in the emerging markets are other factors driving growth in both prescription and over-the-counter drug markets.
Our specialist teams of risk engineers partner with the Swiss Re Institute to ensure our knowledge and expertise of Pharmaceutical industry remains highly relevant and insightful for our clients and brokers. A tool for reaching this goal are our Casualty Risk Trends report, which aim at supporting your underwriting decisions, helping you to focus on the right risks at the right time.
You can download the Pharmaceutical industry report here!
Don't miss also our other casualty risk trends reports:
Casualty Risk Trends 2018: Pharmaceutical industry (PDF, 120 KB)
Swiss Re Corporate Solutions and Airbus Aerial today announced a collaboration that will help companies efficiently identify flood risks and more accurately predict weather-related flood damage.Learn more
Swiss Re Corporate Solutions expands its cyber offering by launching CyberSolution 360°, an innovative risk management solution that combines insurance with cyber attack protection services.Learn more
Swiss Re Corporate Solutions étend son offre cyber en lançant CyberSolution 360°, une solution innovante de gestion des risques qui associe l'assurance à des services de protection contre les attaques cyber.Learn more
The new index-based product is designed to protect companies in Europe from the financial impact of high or low river water levels, such as lost revenue due to business interruption or increased costs due risk mitigation measures.Learn more
23 May 2019
09 May 2019